High-Throughput Screening – Multimedia

During drug development initiatives, analysis of drug-target residence times can lead to improved efficacy. Therefore, residence times are increasingly being used to prioritize molecules early in lead discovery.

Magnetic – microcontact printing of extracellular matrix proteins (ECM) results in cell microarrays (CMA) showing homogeneous cell growth and attachment on defined patterns. This greatly reduces bias in the analysis of cell responses to toxins, drugs or other stimuli.

This list highlights four approaches used to assess toxicology within the field of drug discovery.

Technology trends can greatly increase the capabilities of the laboratory. Here we highlight some of the most popular upcoming trends in the field.

We have developed a homogenous bioluminescent assay (GTPase-Glo) system to analyze these proteins in a simple, convenient “add-mix-read” format.

Learn how NanoBRET assays can be used to interrogate protein events such as epigenetic interactions, adaptor recruitment to membrane receptors and proteasomal recruitment of proteins targeted for degradation.

Mark Wigglesworth PhD, Director of High Throughput Screening at AstraZeneca tells us how using cells as models is improving the success of drug discovery.

The aim of this study was to establish clonal cell lines stably expressing a channelrhodopsin variant and measure membrane potential changes with a fluorescent dye induced by repetitive light-stimulations in a 96-well plate on a kinetic plate reader FDSS 7000EX.

Arun Bhunia's research team is currently developing high throughput nano/biosensor-based screening tools such as the fiber optic, cell-based and light scattering for detection of multi-pathogens and toxins from food.

Jonathan Wingfield, principal scientist at AstraZeneca, talks about the AstraZeneca Open Innovation Portal and the use of acoustic mass spectrometry for high-throughput screening.